What drives this genetic testing business?
Natera is a biotechnology company focused on genetic testing. It develops and runs tests that use DNA analysis to inform medical decisions. The business serves clinicians and patients through laboratory testing services. Its work spans multiple testing needs, including areas tied to reproductive and oncology-related care.
Can rapid revenue growth offset ongoing losses?
FundamentalsFor 2025 (reported in USD), revenue was about USD 2.3 billion, up 35.9% versus the prior year. The cost structure still leaves the company unprofitable on a trailing basis, with a -12.97% operating margin, a -9.05% net profit margin, and a -15.13% return on equity.
Spending on the asset base looks modest relative to revenue, with depreciation and amortization at about USD 41.8 million and capital spending at USD 106.2 million. Total debt stood at USD 80.3 million at year-end.
Is the market overpaying for future profits?
DCF / MultiplesAt USD 222.10 per share, the stock trades well above the DCF’s fair-value range, which remains negative even under the stronger scenario. With a 12.91 trailing price-to-sales ratio, the current price also reflects a high revenue valuation despite the business still showing negative operating and net margins.
Valuation depends on profit recovery
TakeawayThe stock price assumes durability that current profits do not show. The business case depends on keeping growth high while narrowing losses. Durability improves only if margins move toward sustained profitability. If losses persist, the valuation has little fundamental support.